Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Caribou Biosciences develops off-the-shelf CRISPR genome-edited CAR-T and CAR-NK cell therapies to treat cancer patients.
Caribou Biosciences is a clinical-stage biotech company that engineers immune cells to fight cancer. Its big idea is to make these treatments "off-the-shelf" — meaning a doctor could order a ready-made therapy from a freezer instead of building a custom batch from each patient's own cells, which is how today's CAR-T treatments work.
The company's main products are CAR-T and CAR-NK cell therapies, which are white blood cells edited with CRISPR gene-editing tools so they can recognize and attack cancer. Caribou gets its CRISPR technology from a lineage tied to Nobel Prize-winning scientist Jennifer Doudna, who co-founded the company in 2011. Its lead program, an experimental therapy for B-cell lymphomas, is in early and mid-stage human trials. Caribou has no approved products and no product revenue; it earns money mainly through partnerships and licensing deals, and it funds itself largely by selling shares to investors. The appeal of off-the-shelf cell therapy is speed and scale. Making a custom CAR-T for one patient is slow, expensive, and sometimes impossible if the patient's own cells are too weak. A ready-made version could reach more people, faster, at a lower cost. The catch is that the body may reject cells from a donor, so Caribou's editing has to solve immune rejection while keeping the cells potent — the central technical bet of the whole field.
It is a risky, money-hungry business. Clinical trials cost a fortune, failures are common, and Caribou competes with well-funded rivals like Allogene Therapeutics and Arcellx, plus giants such as Novartis and Gilead Sciences that already sell custom CAR-T therapies. A setback in trials or a tough fundraising market can hurt badly; Caribou has trimmed programs and cut staff in the past to conserve cash. For investors, it is a bet that its gene-editing platform can eventually produce a working, scalable cancer treatment.
Saved answer · last researched 15 Nov 2026